$8.45
-0.02[-0.24%]
At close: Apr 26
$8.45
0[0.00%]
After Hours: 7:50PM EDT
Acrivon Therapeutics
(NASDAQ:ACRV)Acrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, Predictions
Acrivon Therapeutics Inc has a consensus price target of $19.8, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, JMP Securities, and Piper Sandler on April 26, 2024, April 25, 2024, and April 25, 2024. With an average price target of $24 between BMO Capital, JMP Securities, and Piper Sandler, there's an implied 184.02% upside for Acrivon Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
JMP Securities
Piper Sandler
HC Wainwright & Co.
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acrivon Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/26/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 195.86% | BMO Capital | Etzer Darout | $18 → $25 | Maintains | Outperform | Get Alert |
| 04/25/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 101.18% | JMP Securities | Silvan Tuerkcan | $14 → $17 | Maintains | Market Outperform | Get Alert |
| 04/25/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 255.03% | Piper Sandler | Joseph Catanzaro | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/25/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 136.69% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 65.68% | Ladenburg Thalmann | Aydin Huseynov | $18 → $14 | Maintains | Buy | Get Alert |
| 04/01/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 113.02% | BMO Capital | Etzer Darout | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 04/01/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 65.68% | JMP Securities | Silvan Tuerkcan | → $14 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/28/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 136.69% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 65.68% | JMP Securities | Silvan Tuerkcan | → $14 | Initiates | → Market Outperform | Get Alert |
| 11/10/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 184.02% | BMO Capital | Etzer Darout | $25 → $24 | Maintains | Outperform | Get Alert |
| 10/05/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 184.02% | Maxim Group | Michael Okunewitch | → $24 | Initiates | → Buy | Get Alert |
| 09/06/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 136.69% | HC Wainwright & Co. | Emily Bodnar | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/18/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 207.69% | JonesTrading | Soumit Roy | → $26 | Initiates | → Buy | Get Alert |
| 08/11/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 136.69% | HC Wainwright & Co. | Emily Bodnar | $21 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 195.86% | Oppenheimer | Matthew Biegler | → $25 | Initiates | → Outperform | Get Alert |
| 05/08/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 195.86% | BMO Capital | Etzer Darout | → $25 | Initiates | → Outperform | Get Alert |
| 05/02/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 184.02% | HC Wainwright & Co. | Emily Bodnar | → $24 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | 184.02% | HC Wainwright & Co. | Emily Bodnar | → $24 | Initiates | → Buy | Get Alert |
| 12/12/2022 | ACRV | Buy Now | Acrivon Therapeutics | $8.45 | — | Cowen & Co. | Joseph Thome | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Acrivon Therapeutics (ACRV)?
The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by BMO Capital on April 26, 2024. The analyst firm set a price target for $25.00 expecting ACRV to rise to within 12 months (a possible 195.86% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by BMO Capital, and Acrivon Therapeutics maintained their outperform rating.
When was the last upgrade for Acrivon Therapeutics (ACRV)?
There is no last upgrade for Acrivon Therapeutics.
When was the last downgrade for Acrivon Therapeutics (ACRV)?
There is no last downgrade for Acrivon Therapeutics.
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on April 26, 2024 so you should expect the next rating to be made available sometime around April 26, 2025.
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $18.00 to $25.00. The current price Acrivon Therapeutics (ACRV) is trading at is $8.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.